Covaxin: Bharat Biotech Supplying 16.5 Lakh Doses Of Its Covid-19 Vaccine Free Of Cost To GovernmentBharat Biotech’s COVAXIN, India’s first indigenous vaccine against coronavirus. (Swarajya Magazine)

Union Health Secretary Rajesh Bhushan on Tuesday (12 January) said that the government has placed an order of 110 lakh vaccine doses from the Serum Institute of India (SII) and 55 lakh doses from Bharat Biotech.

These supplies are bound to reach various centres across the country by 14 January.

Bhushan also informed that individuals will not have a choice over their preferred Covid-19 vaccines due to the logistical limitations and the availability of the vaccine.

“In no country is there is an option available regarding choice of vaccines. We would be staggering our supply orders,” the Health Secretary was quoted in the report.

The SII will be delivering its Covishield Covid-19 vaccine at Rs 200 per dose and Bharat Biotech's Covaxin would be worth Rs 295 per dose excluding the taxes.

Moreover, Bharat Biotech is supplying 16.5 lakh doses of Covaxin free of charge to the government.

NITI Aayog's Dr Vinod Paul has said that both the vaccines are available at an affordable cost in the country as they were made in India. He further assured that their side-effects are negligible.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber
Advertisement